ReviewBlood cancer journal2022
High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions.
Review in Blood cancer journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The [European journal of nuclear medicine and molecular imaging · 2026Pooled it
- International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Guideline
- Efficiency of Automated and Manual Plasma Cell Immunoselection for FISH Analysis in Multiple Myeloma.International journal of laboratory hematology · 2026Article
- Prognosis of Extramedullary Disease in Chinese Newly Diagnosed Multiple Myeloma Patients Treated With Novel Agents-Based Induction Therapy.Cancer medicine · 2026Article
- A Phase I Trial of Iopofosine I 131 and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma.Cancers · 2026Article
- Characteristics, treatment regimens, and outcomes of patients with true extramedullary multiple myeloma: a real-world monocentric analysis.Annals of hematology · 2026Article
- [European journal of nuclear medicine and molecular imaging · 2026Article
- When Timing Matters Most: Early Relapse Outweighs Baseline Risk in Myeloma.Cancer medicine · 2026Article
- Dynamic cytogenetic evolution in multiple myeloma: prognostic implications from diagnosis to first relapse.The oncologist · 2026Article
- Observational
- DKC1: a robust prognostic factor and potential therapeutic target in multiple myeloma.Journal of translational medicine · 2026Article
- Prognostic Significance of SGK1 Expression in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Single-Center Retrospective Study.Stem cells international · 2026Article
- [Value of gene mutation in the prognosis and treatment of multiple myeloma].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Review
- Prognostic Implications of Thrombocytopenia in Chinese Patients With Newly Diagnosed Multiple Myeloma.Cancer medicine · 2025Article
- Improving predictive accuracy in multiple myeloma using a plasma cell profile derived from single-cell RNA sequencing.Haematologica · 2025Article
- Poor prognosis of newly diagnosed multiple myeloma patients with 1p32.3 deletion in single monoallelic deletion and/or in main clone.British journal of haematology · 2025Article
- AI-based body composition analysis of CT data has the potential to predict disease course in patients with multiple myeloma.Scientific reports · 2025Article
- Cardiac biomarkers for risk stratification in newly diagnosed high-risk multiple myeloma in the GMMG-CONCEPT trial.Cardio-oncology (London, England) · 2025Article
- Extramedullary disease in multiple myeloma at diagnosis and over the course of the disease.International journal of hematology · 2025Article
- Outcomes of patients with multiple myeloma undergoing autologous transplant with suboptimal pretransplant response.British journal of haematology · 2025Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Multiple myeloma (MM) is an acquired malignant plasma cell disorder that develops late in life. Although progression free and overall survival has improved across all age, race, and ethnic groups, a subset of patients have suboptimal outcomes and are labeled as having high risk disease. A uniform approach to risk in NDMM remains elusive despite several validated risk stratification systems in clinical use. While we attempt to capture risk at diagnosis, the reality is that many important prognostic characteristics remain ill-defined as some patients relapse early who were defined as low risk based on their genomic profile at diagnosis. It is critical to establish a definition of high risk disease in order to move towards risk-adapted treatment approaches. Defining risk at diagnosis is important to both effectively design future clinical trials and guide which clinical data is needed in routine practice. The goal of this review paper is to summarize and compare the various established risk stratification systems, go beyond the R-ISS and international myeloma working group risk stratifications to evaluate specific molecular and cytogenetic abnormalities and how they impact prognosis independently. In addition, we explore the wealth of new genomic information from recent whole genome/exome sequencing as well as gene expression data and review known clinical factors affecting outcome such as disease burden and early relapse as well as patient related factors such as race. Finally, we provide an outlook on developing a new high risk model system and how we might make sense of co-occurrences, oncogenic dependencies, and mutually exclusive mutations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.